NuCana (NCNA) Income towards Parent Company (2017 - 2025)
NuCana's (NCNA) quarterly Income towards Parent Company came in at -$3.5 million in Q4 2025, down 244.62% year-on-year from $2.4 million in Q4 2024, and down 313.68% quarter-over-quarter from -$844700.7 in Q3 2025.
NuCana (NCNA) Income towards Parent Company (2017 - 2025) Analysis & Trends
NuCana has disclosed Income towards Parent Company across 9 years of filings, most recently posting -$3.5 million for Q4 2025.
- Income towards Parent Company for Q4 2025 came in at -$3.5 million, down 244.62% year-over-year; the trailing twelve-month figure through Dec 2025 was -$40.5 million (down 41.62% YoY), and the FY2025 annual result was -$38.7 million, down 59.38% from the prior year.
- Income towards Parent Company came in at -$3.5 million for Q4 2025 at NuCana, down from -$844700.7 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$844700.7 in Q3 2025 to a low of -$32.6 million in Q2 2025.
- The 5-year median for Income towards Parent Company is -$10.4 million (2024), against an average of -$11.1 million.
- Across the five-year window, Income towards Parent Company surged 90.89% in 2024 and sank 244.62% in 2025, its largest moves.
- NuCana's Income towards Parent Company stood at -$21.2 million in 2021, then climbed by 6.1% to -$19.9 million in 2022, then surged by 44.03% to -$11.1 million in 2023, then soared by 90.89% to -$1.0 million in 2024, then tumbled by 244.62% to -$3.5 million in 2025.
- The last three Income towards Parent Company figures came in at -$3.5 million (Q4 2025), -$844700.7 (Q3 2025), and -$32.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.49 Mn |
| Sep 30, 2025 | -844,700.70 |
| Jun 30, 2025 | -32.61 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | -6.82 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -10.33 Mn |
| Dec 31, 2023 | -11.13 Mn |
| Sep 30, 2023 | -10.26 Mn |
| Jun 30, 2023 | -7.63 Mn |
| Mar 31, 2023 | -10.77 Mn |
| Dec 31, 2022 | -19.89 Mn |
| Sep 30, 2022 | -7.04 Mn |
| Jun 30, 2022 | -6.40 Mn |
| Mar 31, 2022 | -14.00 Mn |
| Dec 31, 2021 | -21.18 Mn |
| Sep 30, 2021 | -13.72 Mn |
| Jun 30, 2021 | -14.92 Mn |
| Mar 31, 2021 | -15.81 Mn |